Development of gene therapy using genome editing technologies
-
- HIRAMATSU Naoto
- Takeda Pharmaceutical Company Limited
-
- UCHIDA Eriko
- National Institute of Health Sciences
-
- INUKAI Naoto
- Takeda Pharmaceutical Company Limited
-
- IWAI Kenichi
- Takeda Pharmaceutical Company Limited
-
- WATANABE Takeshi
- Takeda Pharmaceutical Company Limited
-
- KAWASAKI Hideyoshi
- Astellas Pharma Inc.
-
- TAMURA Kotaro
- Astellas Pharma Inc.
-
- YOSHIMI Eiji
- Astellas Pharma Inc.
-
- TAKAHASHI Norihiko
- Otsuka Pharmaceutical Co., Ltd.
-
- IHARA Tatsuya
- Ono Pharmaceutical Company Limited
-
- FUJIMOTO Kazunori
- Daiichi Sankyo Company Limited
-
- YAMASHITA Akihito
- Sumitomo Dainippon Pharma Co., Ltd.
-
- ONO Takashi
- Ono Pharmaceutical Company Limited
-
- TAKAGI Kan
- Mitsubishi Tanabe Pharma Corporation
-
- ONO Ryuichi
- National Institute of Health Sciences
-
- NAITO Yuki
- Database Center for Life Science (DBCLS)
-
- INOUE Takao
- National Institute of Health Sciences
Bibliographic Information
- Other Title
-
- ゲノム編集技術を用いた遺伝子治療の開発動向
Abstract
<p>Today, gene therapy using gene editing tool (genome editing therapy) is becoming potential new modality treatment. But we need to consider it comes with unconventional safety issues. AMED research group and taskforce established in Japan Pharmaceutical Manufacturers Association have been cooperating in searching of genome editing therapy products and establishing a safety guideline for genome editing therapy. In this session, we will overview the landscape of genome editing therapy products development as the outcome of this co-working activity.</p>
Journal
-
- Annual Meeting of the Japanese Society of Toxicology
-
Annual Meeting of the Japanese Society of Toxicology 47.1 (0), S7-1-, 2020
The Japanese Society of Toxicology
- Tweet
Details 詳細情報について
-
- CRID
- 1390004222615085568
-
- NII Article ID
- 130007898567
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- CiNii Articles
-
- Abstract License Flag
- Disallowed